Poglimet Sustained Release Tablet 5/1000 mg
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
MFDS item code 202106830 · Approved 2021.10.08
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is a combination of dapagliflozin and metformin, used to help adults with type 2 diabetes control their blood sugar in conjunction with diet and exercise therapy. It is particularly effective for patients whose blood sugar is not sufficiently controlled and caution is necessary when used in cases of cardiovascular disease or risk factors. This medication improves blood sugar and helps in diabetes management, contributing to the patient's health.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no previous experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no previous experience of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be adjusted gradually to reduce the gastrointestinal adverse effects of metformin. For patients receiving metformin therapy, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin the patient was taking or an appropriately adjusted dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because changes may cause alterations in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, and without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, treatment with this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
This medication helps in controlling blood sugar levels. It can rarely cause a serious condition called lactic acidosis, where excessive lactic acid builds up in the body, leading to potentially harmful situations. Also, care should be taken when used in conjunction with insulin or sulfonylurea medications as this may lead to hypoglycemia. Patients with poor kidney function, severe infections, heart problems, or dehydration should not use this medication. If you are scheduled to receive iodine contrast for radiological examinations, you must stop taking this medication at least 48 hours prior to the test and ensure normal kidney function before resuming. Pregnant or breastfeeding women should not use this medication, and caution is also advised for children and the elderly. During treatment, kidney function and fluid status should be regularly monitored, and it is important to closely observe for symptoms of hypotension or dehydration. If symptoms like genital infections, urinary tract infections, dizziness, hypoglycemia, or dehydration occur during treatment, consult a doctor immediately. This medication may interact with other drugs, so inform your doctor or pharmacist if you are taking other medications. Excessive alcohol consumption may increase the risk of side effects, hence it should be avoided, and regular testing may be needed as it may lower vitamin B12 levels. Additionally, this medication is usually taken long-term for blood sugar control and if sudden changes in symptoms or adverse reactions occur, immediate notification to healthcare staff is required. Lastly, store this medication out of reach of children and keep it in the original container to maintain its quality.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a sealed container. It is advisable to maintain storage temperatures between 1 to 30 degrees Celsius.
Dark pink, double convex, egg-shaped film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Aprogen Biosciences, Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.